Topics

Paion - FDA outcome April 2020; EMA filing in Q419

04:58 EDT 15 Aug 2019 | FinanzNachrichten

Assuming a successful FDA review of remimazolam for procedural sedation (PS), with an outcome due by 5 April 2020, Paion is set for 20-25% royalties from US sales made by Cosmo. Remimazolam is a sa...

Original Article: Paion - FDA outcome April 2020; EMA filing in Q419

NEXT ARTICLE

More From BioPortfolio on "Paion - FDA outcome April 2020; EMA filing in Q419"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...